Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke

BACKGROUND: The widespread use of tissue plasminogen activator (tPA), the only FDA-approved acute stroke treatment, remains limited by its narrow therapeutic time window and related risks of brain hemorrhage. Normobaric oxygen therapy (NBO) may be a useful physiological strategy that slows down the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Norio, Murata, Yoshihiro, Arai, Ken, Egi, Yasuhiro, Lu, Jie, Wu, Ona, Singhal, Aneesh B, Lo, Eng H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714858/
https://www.ncbi.nlm.nih.gov/pubmed/19604385
http://dx.doi.org/10.1186/1471-2202-10-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714858/
https://www.ncbi.nlm.nih.gov/pubmed/19604385
http://dx.doi.org/10.1186/1471-2202-10-79

Ejemplares similares